Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iothalamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iothalamic Acid SCHEMBL180546 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAKDM4EHIF1ACYP2C19 | |
| Iothalamic Acid SCHEMBL48785 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2LMNAKDM4EHIF1ACYP2C19 | |
| Iothalamic Acid SCHEMBL3060866 | 0.99 | SMN1; SMN2 (0.83) | SMN1; SMN2LMNAKDM4EHIF1ACYP2C19 | |
| Diatrizoic Acid SCHEMBL720469 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4EHIF1ACYP1A2 | |
| Diatrizoic Acid SCHEMBL1685085 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4EHIF1ACYP1A2 | |
| Diatrizoic Acid SCHEMBL107036 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAKDM4EHIF1ACYP1A2 | |
| Diatrizoic Acid SCHEMBL2501947 | 0.91 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAKDM4EHIF1ACYP1A2 | |
| Diatrizoic Acid SCHEMBL468613 | 0.91 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAKDM4EHIF1ACYP1A2 | |
| Ioxitalamic Acid SCHEMBL29730019 | 0.89 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNAKDM4EHIF1ACYP2C19 | |
| Iocarmic Acid SCHEMBL29886627 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNAKDM4EHIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543498-A2 | COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING | Suntec Medical, Inc. (US) | 2025-04-30 | — | — | EP | claimed |
| US-20250121100-A1 | COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING | SUNTEC MEDICAL INC (US) | 2025-04-17 | — | — | US | claimed |
| CN-119698306-A | Compositions and methods for diagnostic imaging | 欣扬生医股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| WO-2023250377-A2 | COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING | SUNTEC MEDICAL, INC. (US) | 2023-12-28 | — | — | WO | claimed |
| EP-4731196-A1 | A MONOLITHIC TABLET COMPOSITION COMPRISING LINAGLIPTIN & METFORMIN | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi (TR) | 2026-04-29 | — | — | EP | disclosed |
| US-12337078-B2 | Organ/tissue decellularization, framework maintenance and recellularization | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4543498-A2 | COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING | Suntec Medical, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250121100-A1 | COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING | SUNTEC MEDICAL INC (US) | 2025-04-17 | — | — | US | disclosed |
| CN-119698306-A | Compositions and methods for diagnostic imaging | 欣扬生医股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024263133-A1 | A MONOLITHIC TABLET COMPOSITION COMPRISING LINAGLIPTIN & METFORMIN | ABDI IBRAHIM ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2024-12-26 | — | — | WO | disclosed |
| CN-118974762-A | System and method for angiographic dose reduction using machine learning | 血管波影像股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023250377-A2 | COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING | SUNTEC MEDICAL, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230310708-A1 | ORGAN/TISSUE DECELLULARIZATION, FRAMEWORK MAINTENANCE AND RECELLULARIZATION | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2023-10-05 | — | — | US | disclosed |
| US-11648335-B2 | Organ/tissue decellularization, framework maintenance and recellularization | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220387433-A1 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM IN PREVENTING OR TREATING ELEVATED PULMONARY VASCULAR PRESSURE OR PULMONARY HEMORRHAGES | AMERICAN REGENT, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| EP-4058026-A2 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM | American Regent, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121100-A1 | COMPOSITION AND METHOD FOR DIAGNOSTIC IMAGING | ABCB4, C5, APOB | SMN1; SMN2 2359/4885LMNA 793/4885KDM4E 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.